clinical trial · NCT05276310
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
Advanced CancerIMC-002
brief summary
This is an Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients with Advanced Cancer Failed to Standard Therapy
started
Jun 2, 2022
primary completion
Dec 17, 2027
completion
Aug 30, 2029
last updated
Apr 24, 2026
detailed description
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IMC-002.
Multiple-dose levels of IMC-002 will be tested in subjects with advanced cancer.
official title
An Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol